LV12881B - NEW TREATMENT METHODS USING PHENETRIC SOLUTIONS - Google Patents

NEW TREATMENT METHODS USING PHENETRIC SOLUTIONS Download PDF

Info

Publication number
LV12881B
LV12881B LVP-02-152A LV020152A LV12881B LV 12881 B LV12881 B LV 12881B LV 020152 A LV020152 A LV 020152A LV 12881 B LV12881 B LV 12881B
Authority
LV
Latvia
Prior art keywords
carbon atoms
alkyl
hydrogen
use according
compound
Prior art date
Application number
LVP-02-152A
Other languages
English (en)
Latvian (lv)
Inventor
Richard Leslie Rudolph
Albert Thomas Derivan
Eric Anthony Muth
Gertrude Virginia Upton
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22181084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV12881(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth filed Critical Wyeth
Publication of LV12881B publication Critical patent/LV12881B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
LVP-02-152A 1993-06-28 2002-08-15 NEW TREATMENT METHODS USING PHENETRIC SOLUTIONS LV12881B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8384893A 1993-06-28 1993-06-28

Publications (1)

Publication Number Publication Date
LV12881B true LV12881B (en) 2002-11-20

Family

ID=22181084

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-02-152A LV12881B (en) 1993-06-28 2002-08-15 NEW TREATMENT METHODS USING PHENETRIC SOLUTIONS

Country Status (15)

Country Link
US (8) US5916923A (de)
EP (3) EP1153603B1 (de)
JP (2) JPH0789851A (de)
KR (1) KR100342762B1 (de)
AT (3) ATE342715T1 (de)
AU (2) AU6592994A (de)
CA (1) CA2126305C (de)
CY (1) CY2315B1 (de)
DE (3) DE69435095T2 (de)
DK (3) DK1738753T3 (de)
ES (3) ES2304041T3 (de)
HK (1) HK1038880B (de)
LV (1) LV12881B (de)
PT (3) PT1738753E (de)
SG (1) SG47711A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
PT667150E (pt) * 1994-02-14 2003-02-28 Wyeth Corp Venlamafaxina e os seus analogos para induzir o aumento do conhecimento
EP1331003B1 (de) * 1996-03-25 2015-08-26 Wyeth LLC Venlafaxinhaltige Arzneizusammensetzung mit verzögerter Wirkstoffabgabe
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
EP1096927A4 (de) * 1998-07-16 2002-09-04 Massachusetts Inst Technology Zusammensetzung für stressbehandlung
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
ES2305606T3 (es) 1999-04-06 2008-11-01 Sepracor Inc. Succinato de o-desmetilvenlafaxina.
US7291646B2 (en) 1999-11-24 2007-11-06 Wyeth Ethers of O-desmethyl venlafaxine
WO2001049679A1 (en) * 1999-12-30 2001-07-12 H. Lundbeck A/S 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
FR2807753B1 (fr) * 2000-04-13 2002-06-07 Adir Nouveaux derives d'heterocycloalkylbenzocyclobutane et d'heteroarylbenzocyclobutane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1360169B2 (de) * 2001-02-12 2017-05-24 Wyeth LLC O-desmethyl-venlafaxine succinat salz
KR100421508B1 (ko) * 2001-08-07 2004-03-09 김정한 항균 및 항진균 활성을 갖는 신규한 펜에틸아민 유도체와이의 염
CN1630631A (zh) * 2001-12-05 2005-06-22 惠氏公司 新的文拉法星盐酸盐多晶型物及其制备方法
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
US20030190352A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Compositions of venlafaxine base
AU2003221535A1 (en) 2002-03-28 2003-10-13 Synthon B.V. Venlafaxine besylate
AR039162A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Formulaciones de venlafaxina de liberacion extendida
US6696496B2 (en) 2002-03-28 2004-02-24 Synthon Bv Low water-soluble venlafaxine salts
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
WO2004047718A2 (en) * 2002-11-28 2004-06-10 Themis Laboratories Private Limited Process for manufacturing sustained release microbeads containing venlafaxine hci
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
WO2004075902A1 (en) * 2003-02-28 2004-09-10 Amedis Pharmaceuticals Ltd. Use of silicon derivatives of venlafaxine for the treatment or prevention of psoriasis or panic disorder
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
US20050226923A1 (en) * 2004-04-07 2005-10-13 Gassert Chad M Venlafaxine compositions in the form of microtablets
US7776358B2 (en) * 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
US20060193912A1 (en) * 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co. Controlled release O-desmethylvenlafaxine formulations
WO2006116149A1 (en) * 2005-04-22 2006-11-02 Wyeth New therapeutic combianations for the treatment or prevention of depression
TW200719886A (en) * 2005-04-22 2007-06-01 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
MX2007013021A (es) * 2005-04-22 2008-01-11 Wyeth Corp Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
WO2006116218A1 (en) * 2005-04-22 2006-11-02 Wyeth Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
JP2008538572A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
KR20080056311A (ko) * 2005-10-19 2008-06-20 테바 파마슈티컬 인더스트리즈 리미티드 고순도1-[2-디메틸아미노-(4-메톡시페닐)에틸)시클로헥산올염산염의 제조 방법
CA2631581C (en) 2005-12-01 2011-05-03 Auspex Pharmaceuticals, Inc. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
CA2629609A1 (en) 2005-12-05 2007-06-14 Wyeth Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols
CA2644662A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
US20080027072A1 (en) * 2006-04-20 2008-01-31 Ampla Pharmaceuticals, Inc. Potentiation of MC4 receptor activity
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
MX2009004247A (es) * 2006-10-25 2009-05-14 Wyeth Corp Metabolitos aislados de hidroxi y n-oxido y derivados de o-desmetilvenlafaxina y metodos de tratamiento.
WO2008140859A1 (en) 2007-03-15 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
WO2009023820A1 (en) * 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination
WO2009065845A1 (en) * 2007-11-20 2009-05-28 Neurosearch A/S A method for treating over-eating disorders
KR100965527B1 (ko) 2008-05-08 2010-06-23 제일약품주식회사 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물
CZ301820B6 (cs) * 2009-02-06 2010-06-30 Zentiva, K.S. Nové soli desvenlafaxinu a zpusob jejich prípravy
US20140116656A1 (en) * 2012-10-25 2014-05-01 Inhon International Co., Ltd Heat dissipation module and electronic device with the same
KR102132304B1 (ko) 2020-02-17 2020-07-09 박광순 접이식 유아용 비데
RU2741226C1 (ru) * 2020-09-08 2021-01-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) Способ профилактики агрессии лиц с интернет-зависимостью

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017637A (en) * 1973-03-26 1977-04-12 American Home Products Corporation Benzylamine analgesics
US3894051A (en) * 1973-07-05 1975-07-08 Colgate Palmolive Co N-methylenedioxyphenylalkyl)-{62 -(alkyl)-disubstituted phenethylamines
US4435449A (en) * 1981-05-14 1984-03-06 Burroughs Wellcome Co. Treatment of minimal brain dysfunction (MBD)
US4824868A (en) * 1982-09-07 1989-04-25 Ciba-Geigy Corporation Propylamine derivatives useful for the treatment of dementia
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
AU566673B2 (en) * 1983-09-15 1987-10-29 F. Hoffmann-La Roche Ag Phenethylamine derivatives
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4611078A (en) * 1983-10-26 1986-09-09 American Home Products Corporation Substituted phenylacetonitriles
US4609758A (en) * 1985-05-09 1986-09-02 American Home Products Corporation Phenoxyethylamine derivatives
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
JP2938463B2 (ja) * 1987-10-22 1999-08-23 マサチユセツツ・インスチチユート・オブ・テクノロジー 月経前又は後期黄体期症候群の処置
US4996235A (en) * 1987-11-25 1991-02-26 Eli Lilly And Company 3,4-diphenylbutanamines
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5006525A (en) * 1989-07-24 1991-04-09 Eli Lilly And Company Dopamine agonists method
US5057515A (en) * 1989-07-24 1991-10-15 Eli Lilly And Company Method for agonizing a dopamine receptor
FI910897A (fi) * 1990-02-28 1991-08-29 Lilly Co Eli Foerbaettringar roerande (s)-norfluoxetin.
EP0449562A3 (en) * 1990-03-29 1992-03-18 Eli Lilly And Company Use of r-fluoxetine as selective serotonin ic-receptor ligands
WO1993009769A1 (en) * 1991-11-15 1993-05-27 Sepracor, Inc. Methods and compositions utilizing pure s(+) isomer fluoxetine
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
TW460478B (en) * 1997-08-15 2001-10-21 Chugai Pharmaceutical Co Ltd Phenethylamine derivatives

Also Published As

Publication number Publication date
DK0639374T3 (da) 2002-05-06
PT1738753E (pt) 2008-06-19
DK1153603T3 (da) 2006-12-18
CA2126305A1 (en) 1994-12-29
PT1153603E (pt) 2007-01-31
DK1738753T3 (da) 2008-08-11
US20080176950A1 (en) 2008-07-24
US6465524B2 (en) 2002-10-15
DE69434872T2 (de) 2007-04-05
CA2126305C (en) 2006-10-17
ES2304041T3 (es) 2008-09-01
US5916923A (en) 1999-06-29
EP1738753B1 (de) 2008-04-23
KR100342762B1 (ko) 2002-11-18
ATE342715T1 (de) 2006-11-15
CY2315B1 (en) 2003-11-14
DE69429895D1 (de) 2002-03-28
EP0639374B1 (de) 2002-02-20
ES2174864T3 (es) 2002-11-16
US6730706B2 (en) 2004-05-04
JPH0789851A (ja) 1995-04-04
US20020052405A1 (en) 2002-05-02
AU5831298A (en) 1998-05-21
DE69434872D1 (de) 2006-11-30
PT639374E (pt) 2002-07-31
DE69429895T2 (de) 2002-08-29
DE69435095D1 (de) 2008-06-05
US6444708B2 (en) 2002-09-03
ES2273764T3 (es) 2007-05-16
SG47711A1 (en) 1998-04-17
US6310101B1 (en) 2001-10-30
HK1038880A1 (en) 2002-04-04
ATE392893T1 (de) 2008-05-15
ATE213407T1 (de) 2002-03-15
HK1038880B (zh) 2006-12-22
EP1153603B1 (de) 2006-10-18
KR950000139A (ko) 1995-01-03
DE69435095T2 (de) 2009-07-02
EP1153603A2 (de) 2001-11-14
US20010012855A1 (en) 2001-08-09
US20010053799A1 (en) 2001-12-20
JP2006117689A (ja) 2006-05-11
US20040110829A1 (en) 2004-06-10
EP1738753A3 (de) 2007-01-31
EP1153603A3 (de) 2003-05-21
AU6592994A (en) 1995-01-05
US6555586B2 (en) 2003-04-29
US20030181517A1 (en) 2003-09-25
EP1738753A2 (de) 2007-01-03
EP0639374A3 (de) 1995-08-02
EP0639374A2 (de) 1995-02-22

Similar Documents

Publication Publication Date Title
LV12881B (en) NEW TREATMENT METHODS USING PHENETRIC SOLUTIONS
US4018895A (en) Aryloxyphenylpropylamines in treating depression
KR100236562B1 (ko) 트라마돌 및 비-스테로이드성 소염제를 함유하는 조성물
US4626549A (en) Treatment of obesity with aryloxyphenylpropylamines
US5530013A (en) Venlafaxine in the inducement of cognition enhancement
FI100091B (fi) Menetelmä kinapriilin värin stabiloimiseksi
HU204504B (en) Process for producing phenoxy-bicyclo-amine derivatives and antidepressive pharmaceutical compositions containing them
US5506270A (en) Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
BG60761B2 (bg) Арилоксифенилпропиламини
PT95760B (pt) Utilizacao de sertralina na preparacao de um medicamento para o tratamento de perturbacoes relacionadas com a ansiedade
GB2087883A (en) Improvements in or relating to 3--aryloxy-3-phenylpropylamines
US20040019101A1 (en) Methods of treating gastrointestinary and genitourinary pain disorders
PT80805B (pt) Processo para a preparacao de derivados de fluorolilamina
EP0667150B1 (de) Venlafaxin und seine Analoga zum Herbeiführen einer Verbesserung der kognitiven Funktionen
EP0302757A2 (de) Antiemetisch wirksame Serotonin-Depletoren
AU744990B2 (en) New treatment using phenethylamine derivatives
US20080176951A1 (en) Methods of treating gastrointestinary and genitourinary pain disorders
JPH078864B2 (ja) ２―アルキル―３―ベンゾイルベンゾフラン
EP0053379A1 (de) Mittel gegen peptische Geschwüre
JPH05271189A (ja) インシュリン耐性被験者の高血圧症治療用ｎ´−置換ｎ−フェニルスルホニル尿素含有医薬組成物
JP2005500344A (ja) ３−アリールオキシ−３−フェニルプロパンアミンを用いた慢性疼痛の治療